Cargando…
Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life
Despite in vitro activity of interferon-β (IFN-β) against SARS-CoV-2 infection, its clinical efficacy remains controversial. We evaluated the impact of IFN-β treatment in a cohort of 3590 patients hospitalized with COVID-19 during March–April 2020. The primary endpoint was a composed variable of adm...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739717/ https://www.ncbi.nlm.nih.gov/pubmed/36498527 http://dx.doi.org/10.3390/jcm11236952 |
_version_ | 1784847877645795328 |
---|---|
author | Casado, José L. Vizcarra, Pilar Del Rey, José M. Soriano, María Cruz Rodriguez-Dominguez, Mario Manzano, Luis Acero, Julio Palomar-Fernandez, Carmen Vallejo, Alejandro |
author_facet | Casado, José L. Vizcarra, Pilar Del Rey, José M. Soriano, María Cruz Rodriguez-Dominguez, Mario Manzano, Luis Acero, Julio Palomar-Fernandez, Carmen Vallejo, Alejandro |
author_sort | Casado, José L. |
collection | PubMed |
description | Despite in vitro activity of interferon-β (IFN-β) against SARS-CoV-2 infection, its clinical efficacy remains controversial. We evaluated the impact of IFN-β treatment in a cohort of 3590 patients hospitalized with COVID-19 during March–April 2020. The primary endpoint was a composed variable of admission to intensive care unit (ICU)/death. Overall, 153 patients (4%) received IFN-β. They were significantly more severely ill, with a worse clinical and analytical situation, explaining a higher ICU admission (30% vs. 17%; p < 0.01), and a shorter time to the composed variable. In a Cox regression analysis, older age, lymphopenia, renal failure, or increased neutrophil-to-lymphocyte ratio were associated with a greater hazard ratio (HR) of admission at ICU/death. Notably, the HR of IFN-β for the outcome variable was no longer significant after adjustment (HR, 1.03; 95% CI, 0.82–1.30), and different sensitivity analysis (early IFN use, ICU admission) showed no changes in the estimates. A propensity score matching analysis showed no association of IFN-β therapy and outcome. In conclusion, in this large cohort of hospitalized COVID-19 patients, IFN-β was used mainly in patients with advanced disease, reflecting an important bias of selection. After adjusting by severity, IFN-β was not associated with a higher rate of ICU admission or mortality. |
format | Online Article Text |
id | pubmed-9739717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97397172022-12-11 Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life Casado, José L. Vizcarra, Pilar Del Rey, José M. Soriano, María Cruz Rodriguez-Dominguez, Mario Manzano, Luis Acero, Julio Palomar-Fernandez, Carmen Vallejo, Alejandro J Clin Med Article Despite in vitro activity of interferon-β (IFN-β) against SARS-CoV-2 infection, its clinical efficacy remains controversial. We evaluated the impact of IFN-β treatment in a cohort of 3590 patients hospitalized with COVID-19 during March–April 2020. The primary endpoint was a composed variable of admission to intensive care unit (ICU)/death. Overall, 153 patients (4%) received IFN-β. They were significantly more severely ill, with a worse clinical and analytical situation, explaining a higher ICU admission (30% vs. 17%; p < 0.01), and a shorter time to the composed variable. In a Cox regression analysis, older age, lymphopenia, renal failure, or increased neutrophil-to-lymphocyte ratio were associated with a greater hazard ratio (HR) of admission at ICU/death. Notably, the HR of IFN-β for the outcome variable was no longer significant after adjustment (HR, 1.03; 95% CI, 0.82–1.30), and different sensitivity analysis (early IFN use, ICU admission) showed no changes in the estimates. A propensity score matching analysis showed no association of IFN-β therapy and outcome. In conclusion, in this large cohort of hospitalized COVID-19 patients, IFN-β was used mainly in patients with advanced disease, reflecting an important bias of selection. After adjusting by severity, IFN-β was not associated with a higher rate of ICU admission or mortality. MDPI 2022-11-25 /pmc/articles/PMC9739717/ /pubmed/36498527 http://dx.doi.org/10.3390/jcm11236952 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Casado, José L. Vizcarra, Pilar Del Rey, José M. Soriano, María Cruz Rodriguez-Dominguez, Mario Manzano, Luis Acero, Julio Palomar-Fernandez, Carmen Vallejo, Alejandro Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life |
title | Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life |
title_full | Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life |
title_fullStr | Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life |
title_full_unstemmed | Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life |
title_short | Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life |
title_sort | lost in translation: evaluation of subcutaneous interferon-β treatment for sars-cov-2 infection in real life |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739717/ https://www.ncbi.nlm.nih.gov/pubmed/36498527 http://dx.doi.org/10.3390/jcm11236952 |
work_keys_str_mv | AT casadojosel lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife AT vizcarrapilar lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife AT delreyjosem lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife AT sorianomariacruz lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife AT rodriguezdominguezmario lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife AT manzanoluis lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife AT acerojulio lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife AT palomarfernandezcarmen lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife AT vallejoalejandro lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife AT lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife |